Trial Profile
Clinical Trials Insight: 700035340
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Jul 2008
Price :
$35
*
At a glance
- Drugs Reximmune C (Primary) ; Rexin-G (Primary)
- Indications Breast cancer; Colorectal cancer; Leiomyosarcoma; Pancreatic cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Epeius Biotechnologies Corporation
- 16 Jul 2008 New trial record.